Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Anthera Pharmaceuticals Inc.
  • BIND Therapeutics Inc.
  • Celgene Corp.
  • Celldex Therapeutics Inc.
  • Cerus Corp.
  • Compugen Ltd.
  • Cytokinetics Inc.
  • CytoSorbents Corp.
  • Galapagos NV
  • Incyte Corp.
  • MorphoSys
  • Novavax Inc.
  • Omeros Corp.
  • OncoGenex Pharmaceuticals Inc.
  • OXiGENE Inc.
  • Peregrine Pharmaceuticals Inc.
  • Pharmacyclics Inc.
  • Pluristem Therapeutics Inc.
  • Prana Biotechnology Ltd.
  • Threshold Pharmaceuticals Inc.
  • Verastem Inc.

George Zavoico

MLV & Co

Image: George Zavoico

Dr. George Zavoico, managing director and senior equity analyst at MLV & Co., has more than 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector. Previously, Zavoico was an equity research analyst in the healthcare sector at Westport Capital Markets and Cantor Fitzgerald. Prior to working as an analyst, Zavoico established his own consulting company serving the biotech and pharmaceutical industries, providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). Zavoico has a bachelor's degree in biology from St. Lawrence University and a Ph.D. in physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and Harvard Medical School/Brigham & Women's Hospital. He has published more than 30 papers in peer-reviewed journals and has coauthored four book chapters.




Recent Interviews

Ebola's Silver Lining: MLV & Co.'s George Zavoico (11/12/14) A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV & Co. has that advantage, having been a senior investigator at a large pharma before moving on to research at smaller, pure biotech firms. In this interview with The Life Sciences Report, Zavoico brings a wealth of experience to bear on the valuations of smaller companies with phenomenal growth prospects, and discusses how the quest for a cure for Ebola could disruptŚand improveŚour approach to medical crises.

Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound (11/6/14) When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance of Streetwise Reports' Biotechnology Watchlist to date reflects this trend: The portfolio lingered in negative territory after the late-winter punch, and hovers near breakeven as of Nov. 3. To get a handle on the drivers of small-cap stock price volatility, The Life Sciences Report turned to a pair of the analysts who selected companies for the 2014 Watchlist, John McCamant of the Medical Technology Stock Letter and George Zavoico of MLV & Co. In this recap, the two experts offer updates on the companies they selected for the portfolio.

Shining a Light on Overlooked and Underfollowed Biotechs: George Zavoico (3/6/14) Prospecting for hidden biotech gems makes sense, says H.C. Wainwright & Co. Managing Director George Zavoico, who recently joined the firm's healthcare equity research team. The digging can be hard, but the rewards of successful diligence are huge. In this interview with The Life Sciences Report, Zavoico takes readers on a discovery tour that follows clinical trial data to new ideas that could bring windfalls to portfolios down the road.

Recent Quotes

"GLPG is notable and underappreciated." (11/12/14) Galapagos NV - The Life Sciences Report Interview with George Zavoico Moreá>

"Positive data in the pancreatic or the sarcoma studies could take THLD shares to my target." (11/12/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico Moreá>

"We see a pretty healthy revenue stream coming from OMER's Omidria." (11/12/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico Moreá>

"We believe that OMER will become profitable in 2016." (11/6/14) Omeros Corp. - The Life Sciences Report Biotech Watchlist Update with George Zavoico Moreá>

"We continue to believe OMER's OMS824 to be safe and expect the Phase 2 trial to resume." (10/22/14) Omeros Corp. - George Zavoico, MLV & Co Moreá>

"We think THLD could become profitable in 2016 based on revenue from sales of TH-302." (10/13/14) Threshold Pharmaceuticals Inc. - George Zavoico, MLV & Co Moreá>

"I believe THLD's drug works, and momentum for the company is building." (3/6/14) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico Moreá>

"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico Moreá>

more comments

"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials." (3/6/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico Moreá>

"PSTI announced positive results of a preclinical study of its PLX cells." (11/5/13) Pluristem Therapeutics Inc. - George Zavoico, MLV & Co Moreá>

"We view the expansion of PSTI's trial into Israel as an effective strategy to accelerate patient enrollment." (10/2/13) Pluristem Therapeutics Inc. - George Zavoico, MLV & Co Moreá>

"PSTI's preclinical study provides additional evidence of efficacy." (10/1/13) Pluristem Therapeutics Inc. - George Zavoico, MLV & Co Moreá>

(8/15/13) Threshold Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico Moreá>

"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.